0000950170-23-029500.txt : 20230623 0000950170-23-029500.hdr.sgml : 20230623 20230623073129 ACCESSION NUMBER: 0000950170-23-029500 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230623 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230623 DATE AS OF CHANGE: 20230623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acasti Pharma Inc. CENTRAL INDEX KEY: 0001444192 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35776 FILM NUMBER: 231034869 BUSINESS ADDRESS: STREET 1: 3009, BOUL. DE LA CONCORDE EAST STREET 2: SUITE 102 CITY: LAVAL STATE: A8 ZIP: H7E 2B5 BUSINESS PHONE: 450-686-4555 MAIL ADDRESS: STREET 1: 3009, BOUL. DE LA CONCORDE EAST STREET 2: SUITE 102 CITY: LAVAL STATE: A8 ZIP: H7E 2B5 8-K 1 acst-20230623.htm 8-K 8-K
0001444192false00014441922023-06-232023-06-23

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2023

 

 

ACASTI PHARMA INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Quebec

001-35776

98-1359336

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3009, boul. de la Concorde East

Suite 102

 

Laval, Quebec

 

H7E 2B5

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 450 686-4555

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Shares, no par value per share

 

ACST

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition."

 

On June 23, 2023, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal year ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing or document.

Item 9.01 Exhibits.

(d) Exhibits

 

Exhibit

 

Description

99.1

 

Press Release dated June 23, 2023

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

ACASTI PHARMA INC.

 

 

 

 

Date:

June 23, 2023

By:

/s/ Prashant Kohli

 

 

 

Prashant Kohli
Chief Executive Officer

 

 EX-99.1 2 acst-ex99_1.htm EX-99.1 EX-99.1


Acasti Pharma Reports Fiscal Year 2023 Operational Results

LAVAL, Québec, June 23, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial and operational results for the fiscal year ended March 31, 2023.

Recent Highlights

•
United States Food and Drug Administration (FDA) has confirmed the 505(b)(2) regulatory pathway for GTX-104 and that the GTX-104-002 PK study may have met the criteria for a scientific bridge.
•
Successfully submitted GTX-104 Pivotal Phase 3 Safety Study protocol Investigational New Drug (IND) amendment to the FDA with the expectation that a first patient will be dosed in the second half of calendar 2023.
•
Implemented strategic transformation of operating model to an agile biopharma reflecting its operational focus on GTX-104. In alignment with the new operating model, Acasti has brought on a small and highly experienced new management team with deep subject matter knowledge and direct, hands-on clinical trial experience in aSAH.
•
Significant extension of the Company's cash runway which is expected to be sufficient to fund the Company through calendar Q2 2025 and the achievement of critical value inflection milestones, including a potential New Drug Application (NDA) filing for GTX-104.
•
Evaluation of strategic alternatives to maximize value of de-prioritized pipeline assets (GTX-102 and GTX-101).
•
The Company finished the fiscal year ended March 31, 2023, with $27.9 million in cash, cash equivalents and short-term investments.

Management Discussion

Prashant Kohli, Chief Executive Officer of Acasti, said, "After receiving positive clarifying feedback from the FDA on the proposed Phase 3 Safety Study for GTX-104 whereby they concurred with the suitability of the 505(b)(2) regulatory pathway and that Acasti's GTX-104-002 PK study may have met the criteria for a scientific bridge, we moved swiftly to submit the full protocol for our pivotal Phase 3 Safety Study in May 2023. Further, we implemented a strategic realignment plan to maximize shareholder value, including a strategic transformation of Acasti's operating model to that of an agile biopharma company which we believe allows our cash runway to be sufficient to achieve a potential NDA filing for GTX-104 in 2025. Our new, highly motivated, and energized organization is entirely focused on achieving critical value inflection milestones in the quarters and years to come."

FY 2023 Financial Results

The Company's consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars.

Research and development expenses, net of government assistance for the twelve months ended March 31, 2023, totaled $9.9 million compared to $5.6 million for the twelve months ended March 31, 2022. Our research and development during the year ended March 31, 2023 was focused primarily on three clinical development programs GTX-104, GTX-102, and GTX-101 drug candidates. Due to the strategic realignment announced on April 4, 2023, the Company will focus its future research and development expenses exclusively on GTX-104. Future development of GTX-102 and GTX-101 will depend on additional dedicated funding or the signing of a strategic partnership. Research and development expenses during the year ended March 31, 2022, related to the completion of our TRILOGY Phase 3 clinical program for our former drug candidate CaPre, as well as the initiation and progression of development work related to GTX-104, GTX-102 and GTX-101.

General and administrative expenses for the twelve months ended March 31, 2023 were $7.6 million compared to $9.3 million for the twelve months ended March 31, 2022. The decrease was primarily a result of decreased legal, tax, accounting and other professional fees related to the Grace merger for the year ended March 31, 2022. Due to the strategic realignment announced on April 4, 2023, the Company is over time discontinuing its operations in Canada and has proceeded to lay off substantially all its workforce, allowing Acasti's new management team to rebuild a leaner organization in the United States.

As a result of the strategic realignment plan announced on April 4, 2023 to prioritize resources to GTX-104, and away from GTX-101 and GTX-102, the company incurred an impairment of intangible assets of $28.7 million, and an impairment of goodwill of $4.8 million, for the period ended March 31, 2023.

Loss from operating activities for the twelve months ended March 31, 2023 was $52.1 million compared to a loss of $15.6 million for the twelve months ended March 31, 2022. The change is primarily a result of the combined $33.5 million impairments to intangible assets and goodwill mentioned.

For the twelve months ended March 31, 2022, a financial gain of $5.1 million resulted mostly due to the decrease in the fair value of the derivative warrant liabilities.

Net loss and total comprehensive loss for the twelve months ended March 31, 2023 was $(42.4) million, or $(0.95) loss per share, compared to a net loss of $(9.8) million, or $(0.27) income per share, for the twelve months ended March 31, 2022. The change is primarily a result of the combined $33.5 million impairments to intangible assets and goodwill mentioned.

Cash, cash equivalents and short-term investments totaled $27.9 million as of March 31, 2023, compared to $43.7 million in cash, cash equivalents and short-term investments as of March 31, 2022. Based on management's current projections, current cash, cash equivalents and short-term investments are expected to be sufficient to fund the Company through calendar Q2 2025, facilitating achievement of critical value inflection milestones, including a potential New Drug Application (NDA) filing for GTX-104.

About Acasti

Acasti is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Acasti's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Acasti's lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Acasti's lead clinical asset, GTX-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull.

For more information, please visit: https://www.acastipharma.com/en.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Such forward looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements containing the terms "believes," "belief," "expects," "intends," "anticipates," "estimates", "potential," "should," "may," "will," "plans," "continue", "targeted" or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements in this press release, including on the Company's anticipated cash runway, are based upon Acasti's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions of the planned Phase 3 safety study for GTX-104; (ii) regulatory requirements or developments and the outcome and timing of the proposed IND application for GTX-104; (iii) changes to clinical trial designs and regulatory pathways; (iv) legislative, regulatory, political and economic developments; (v) actual costs associated with Acasti's clinical trials as compared to management's current expectations; and (vi) the projected extension of the Company's cash runway to calendar Q2 2025. The foregoing list of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and are filed by Acasti from time to time with the Securities and Exchange Commission and Canadian securities regulators. All forward-looking statements contained in this press release speak only as of the date on which they were made. Acasti undertakes no obligation to update

such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable securities laws. The NASDAQ does not accept responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Acasti Contact:

Prashant Kohli
Chief Executive Officer
Tel: 450-686-4555
Email:info@acastipharma.com

www.acasti.com

Investor Relations:
Robert Blum
Lytham Partners, LLC
602-889-9700
ACST@lythampartners.com

ACASTI PHARMA INC.

 

 

 

Condensed Consolidated Balance Sheet

 

 

 

(Unaudited)

 

 

 

 

 

 

 

 

As of

 

March 31, 2023

 

March 31, 2022

(Expressed in thousands of U.S. dollars except share data)

$

 

$

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

27,875

 

30,339

Short-term investments

15

 

13,322

Receivables

802

 

548

Assets held for sale

—

 

352

Prepaid expenses

598

 

720

Total current assets

29,290

 

45,281

 

 

 

 

Operating lease right of use asset

463

 

315

Equipment

104

 

250

Intangible assets

41,128

 

69,810

Goodwill

8,138

 

12,964

Total assets

79,123

 

128,620

 

 

 

 

Liabilities and Shareholders' equity

 

 

 

Current liabilities:

 

 

 

Trade and other payables

3,336

 

3,156

Operating lease liability

75

 

104

Total current liabilities

3,411

 

3,260

 

 

 

 

Derivative warrant liabilities

—

 

10

Operating lease liability

410

 

191

Deferred tax liability

7,347

 

16,889

 

 

 

 

Total liabilities

11,168

 

20,350

 

 

 

 

Shareholders' equity:

 

 

 

Common shares, no par value per share; unlimited shares authorized as
of March 31, 2023 and March 31, 2022; 44,612,831 and 44,288,183
shares issued and outstanding as of March 31, 2023 and March 31, 2022,
respectively

258,294

 

257,990

Additional paid-in capital

13,965

 

12,154

Accumulated other comprehensive loss

(6,038)

 

(6,037)

Accumulated deficit

(198,266)

 

(155,837)

Total shareholder's equity

67,955

 

108,270

 

 

 

 

Commitments and contingencies

 

 

 

Total liabilities and shareholders' equity

79,123

 

128,620

ACASTI PHARMA INC.

 

 

 

Condensed Consolidated Statements of Loss and Comprehensive Loss

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

Year ended
March 31, 2023

 

Year ended
March 31, 2022

 

 

(Expressed in thousands of U.S. dollars except share and per data)

$

 

$

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

Research and development expenses, net of government assistance

(9,972)

 

(5,559)

 

 

General and administrative expenses

(7,614)

 

(9,263)

 

 

Sales and marketing

(661)

 

(518)

 

 

Impairment of intangible assets

(28,682)

 

—

 

 

Impairment of goodwill

(4,826)

 

—

 

 

Impairment of assets held for sale

(400)

 

(249)

 

 

Loss from operating activities

(52,155)

 

(15,589)

 

 

Other income

184

 

5,122

 

 

Loss before income tax recovery

(51,971)

 

(10,467)

 

 

 

 

 

 

 

 

Income tax recovery

9,542

 

648

 

 

 

 

 

 

 

 

Net loss and total comprehensive loss

(42,429)

 

(9,819)

 

 

 

 

 

 

 

 

Basic and diluted loss per share

(0.95)

 

(0.27)

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding

44,612,831

 

36,841,762

 

 

 

 

 EX-101.SCH 3 acst-20230623.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 acst-20230623_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 5 acst-20230623_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Jun. 23, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 23, 2023
Entity Registrant Name ACASTI PHARMA INC.
Entity Central Index Key 0001444192
Entity Emerging Growth Company false
Securities Act File Number 001-35776
Entity Incorporation, State or Country Code A8
Entity Tax Identification Number 98-1359336
Entity Address, Address Line One 3009, boul. de la Concorde East
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Laval
Entity Address, State or Province QC
Entity Address, Postal Zip Code H7E 2B5
City Area Code 450
Local Phone Number 686-4555
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value per share
Trading Symbol ACST
Security Exchange Name NASDAQ
XML 7 acst-20230623_htm.xml IDEA: XBRL DOCUMENT 0001444192 2023-06-23 2023-06-23 0001444192 false 8-K 2023-06-23 ACASTI PHARMA INC. A8 001-35776 98-1359336 3009, boul. de la Concorde East Suite 102 Laval QC H7E 2B5 450 686-4555 false false false false Common Shares, no par value per share ACST NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports acst-20230623.htm acst-20230623.xsd acst-20230623_lab.xml acst-20230623_pre.xml acst-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "acst-20230623.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "acst-20230623.htm" ] }, "labelLink": { "local": [ "acst-20230623_lab.xml" ] }, "presentationLink": { "local": [ "acst-20230623_pre.xml" ] }, "schema": { "local": [ "acst-20230623.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "acst", "nsuri": "http://www.acastipharma.com/20230623", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20230623.htm", "contextRef": "C_4c2dbb7e-8835-4834-835e-b74cc45c343c", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20230623.htm", "contextRef": "C_4c2dbb7e-8835-4834-835e-b74cc45c343c", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.acastipharma.com/20230623/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-029500-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-029500-xbrl.zip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